Kaplan and Sadocks Comprehensive Textbook of Psychiatry, 11e

xvi

Contents

33.7 Serotonin Antagonists/Inverse Agonists

33.11b Cholinesterase Inhibitors and Memantine

3215

3335

Samir A. Sabbag, M.D., Zelde Espinel, M.D., M.P.H., Luminita Luca, M.D., Ph.D., and Elizabeth A. Crocco, M.D.

33.7a Pimavanserin

3215 Joan M. Striebel, M.D., Jennifer A. O’Day, M.D., Nekisa Haghighat, M.D., M.P.H., and Stephen M. Stahl, M.D., Ph.D., D.Sc. (Hon.)

33.12 Histamine Modulators

3345

33.8 Noradrenaline Modulators

3219

33.12a Histamine Blockers and Enhancers

33.8a α 2 -Adrenergic Receptor

3345

Sasson Zemach, M.D., and Abraham Weizman, M.D.

Agonists: Clonidine, Clonidine Extended Release, Guanfacine, and Guanfacine Extended Release

33.13 Pharmacological Treatments of Substance Abuse

3219

3350

Eric Hollander, M.D., and Migena Dervishi, M.D. 33.8b β -Adrenergic Receptor Antagonists

33.13a Opioid Receptor Modulators

3350 33.13a.1 Opioid Maintenance Treatments: Methadone and Buprenorphine ��� 3350

3224

Migena Dervishi, M.D., and Eric Hollander, M.D.

33.9 GABA Enhancers

3229

Jonathan R. Buchholz, M.D., Kelly Barth, D.O., and Andrew J. Saxon, M.D.

33.9a Barbiturates and Similarly Acting Substances Steven L. Dubovsky, M.D., and Dori Marshall, M.D. 33.9b Benzodiazepine Receptor Agonists and Antagonists

3229

33.13a.2 Opioid Receptor Antagonists: Naltrexone and Nalmefene

3237

3357

Steven L. Dubovsky, M.D., and Dori Marshall, M.D. 33.10 Cation Function Modulators and Lithium (“Mood Stabilizers”)

Oluwole O. Jegede, M.D., M.P.H., Stephanie S. O’Malley, Ph.D.,

3256 33.10a Calcium Channel Inhibitors ��� 3256 Steven L. Dubovsky, M.D., and Dori Marshall, M.D. 33.10b Gabapentin, Topiramate, Tiagabine, Levetiracetam, Zonisamide, and Pregabalin ��� 3264 Hiroyuki Uchida, M.D., Ph.D. 33.10c Carbamazepine 3277 Robert M. Post, M.D., and Mark A. Frye, M.D. 33.10d Lamotrigine 3295 Robert M. Post, M.D. 33.10e Valproate 3300 Robert M. Post, M.D., and Mark A. Frye, M.D. 33.10f Lithium 3313 Robert H. Belmaker, M.D.

Tiffany Arnold, B.S., M.D., Katherine S. Pier, M.D., and Srinivas B. Muvvala, M.D., M.P.H. 33.13b Disulfiram and Acamprosate ��� 3367 Katherine S. Pier, M.D. 33.14 Fast-Acting Pharmacologic Treatments 3378 33.14a Esketamine and Ketamine 3378 Carlos A. Zarate, Jr., M.D., and Lawrence T. Park, A.M., M.D. 33.14b MDMA, Psilocybin, Ayahuasca, and Ibogaine 3386 David Nutt, F.R.C.P., F.R.C.Psych.,

F.B.Ph.S., F.Med.Sci., D.Laws., and David Erritzoe, M.D., Ph.D., M.R.C.Psych.

33.15 Hormone Receptor Enhancers

3391

33.15a Melatonin Receptor Agonists

33.11 Acetylcholine Blockers and Enhancers

3391

3324

Tawny L. Smith, Pharm.D., B.C.P.P., and D. Jeffrey Newport, M.D., M.S., M.Div.

33.11a Anticholinergics and Amantadine

3324

Copyright © 2025 Wolters Kluwer, Inc. Unauthorized reproduction of this content is prohibited. Samoon Ahmad, M.D.